Chembio to Report COVID-19 Product Development Plans and Preliminary Estimated Second Quarter 2020 Revenue Results
July 01 2020 - 5:00PM
Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading
global point-of-care diagnostic company focused on infectious
diseases, today announced today that it will issue, after the U.S.
financial markets close on Monday, July 6, 2020, press releases
with respect to its current plans for COVID-19 product development
and regulatory approvals and its preliminary estimates of revenue
results for the quarter ended June 30, 2020.
Chembio will host a conference call on Tuesday, July 7, 2020, at
8:00 am (Eastern time) to discuss the information described in
those press releases and related business and financial matters.
Interested parties can participate in the conference call by
dialing 877-407-0778 (U.S. toll-free) or 201-689-8565
(international) or joining a live audio webcast available at
www.chembio.com/investors/calendar-of-events/. Following the call,
a replay of the call is expected to be available through July 10,
2020, by dialing 877-481-4010 (U.S. toll-free) or 919-882-2331
(international), conference ID code 35572, or by accessing
www.chembio.com/investors/calendar-of-events/.
About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on
detecting and diagnosing infectious diseases, including COVID-19,
sexually transmitted disease, and fever and tropical disease. The
company’s proprietary DPP technology platform, which uses a small
drop of blood from the fingertip or alternative sample types,
provides high-quality, cost-effective results in approximately 15
minutes. Coupled with Chembio’s extensive scientific expertise, its
novel DPP technology offers broad market applications beyond
infectious disease. Chembio’s products are sold globally, directly
and through distributors, to hospitals and clinics, physician
offices, clinical laboratories, public health organizations,
government agencies, and consumers. Learn more at
www.chembio.com.
DPP is Chembio’s registered trademark. For convenience, this
trademark appears in this release without ® symbols, but that
practice does not mean that Chembio will not assert, to the fullest
extent under applicable law, its rights to the trademark.
Contact:Philip TaylorGilmartin Group(415)
937-5406investor@chembio.com
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Apr 2023 to Apr 2024